Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Svetlana Babajanyan"'
Autor:
Andrew G Gianoukakis, Jennifer H Choe, Daniel W Bowles, Marcia S Brose, Lori J Wirth, Taofeek Owonikoko, Svetlana Babajanyan, Francis P Worden
Publikováno v:
European Thyroid Journal, Vol 13, Iss 1, Pp 1-13 (2024)
Background: The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear. Thus, we evaluated the real-world practice patterns and outcomes
Externí odkaz:
https://doaj.org/article/4362b3a229454c4c935fbc2568fe4ec8
Autor:
Scott F. Huntington, Sreevalsa Appukkuttan, Wenyi Wang, Yuxian Du, Sari Hopson, Svetlana Babajanyan
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 9, Iss 2 (2022)
**Background:** A consensus is lacking on optimal treatment sequencing for follicular lymphoma (FL), the most common indolent lymphoma. FL is incurable, and many patients require multiple lines of therapy for successive relapses. Guidelines provide n
Externí odkaz:
https://doaj.org/article/0aaaf38c96e9474fae346c6e3cd9c96b
Autor:
Marcia S. Brose, Johannes W.A. Smit, Chia-Chi Lin, Masayuki Tori, Daniel W. Bowles, Francis Worden, Daniel Hueng-Yuan Shen, Shih-Ming Huang, Hui-Jen Tsai, Maria Alevizaki, Robin P. Peeters, Shunji Takahashi, Pavel Rumyantsev, Rongjin Guan, Svetlana Babajanyan, Kirhan Ozgurdal, Iwao Sugitani, Fabian Pitoia, Livia Lamartina
Publikováno v:
Thyroid, 32(9), 1059-1068. Mary Ann Liebert Inc.
Thyroid, 32, 1059-1068
Thyroid, 32, 9, pp. 1059-1068
Thyroid, 32, 1059-1068
Thyroid, 32, 9, pp. 1059-1068
Background: Sorafenib and lenvatinib are multikinase inhibitors (MKIs) approved for patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). There is no consensus on when to initiate MKI treatment. The objective of thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412d862c328d67e20e52d1c048424db1
https://pure.eur.nl/en/publications/2b1c47c4-dfac-404d-afa7-098c439f1f69
https://pure.eur.nl/en/publications/2b1c47c4-dfac-404d-afa7-098c439f1f69
Autor:
Andrea Ferreira-Gonzalez, Gilbert C. Ko, Sreevalsa Appukkuttan, Brian Hocum, Sohul Shuvo, Svetlana Babajanyan
Publikováno v:
Cancer Research. 83:1964-1964
Introduction: NGS utilization has increased over the last decade, although opportunities for improvement remain. Evaluation of trends in NGS utilization between race/ethnic groups will provide a better understanding of potential populations that may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deb308a0b92c329aeb42d3d5c90af6b2
https://doi.org/10.1158/1538-7445.am2023-1964
https://doi.org/10.1158/1538-7445.am2023-1964
Autor:
Stacey Simmons, Sreevalsa Appukkuttan, Lonnie Wen, Krishna Tangirala, Neal D. Shore, Svetlana Babajanyan
Publikováno v:
PharmacoEconomics Open
Background Castration-resistant prostate cancer (CRPC) is associated with high costs and healthcare resource utilization (HCRU). Objective This study followed patients with CRPC through their continuum of care and analyzed claims data regarding treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff9ed1d194e2193f7e3004a4a5619c8d
http://europepmc.org/articles/PMC7426332
http://europepmc.org/articles/PMC7426332
Publikováno v:
Colorectal Cancer. 10
There is limited evidence-based guidance regarding treatment sequencing and outcomes following regorafenib in patients with refractory metastatic colorectal cancer (mCRC). A targeted literature review was conducted to identify studies with clinical o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f2b328e61d52ecd4d7bc04942b1854d
https://doi.org/10.2217/crc-2022-0006
https://doi.org/10.2217/crc-2022-0006
Autor:
Robert C.G. Martin, Elizabeth H. Bruenderman, Jean Francois H. Geschwind, Pierre M. Gholam, Brendan M. McGuire, Parvez S. Mantry, Arun J. Sanyal, Ellen Zigmont, Bilal Piperdi, Pamela K. Foreman, Rebecca A. Miksad, Allen Lee Cohn, Alec Goldenberg, Svetlana Babajanyan
Publikováno v:
The American Journal of Surgery. 213:688-695
Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge. One option is sorafenib, although little is known about its safety and to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faa50a17bfddc60c4508eb16013c65a4
https://doi.org/10.1016/j.amjsurg.2016.10.006
https://doi.org/10.1016/j.amjsurg.2016.10.006
Autor:
Sreevalsa Appukkuttan, Mecide Gharibo, Miriam L. Zichlin, Svetlana Babajanyan, Emilie Duchesneau, Rachel H. Bhak, Avin Yaldo, Mei Sheng Duh
Publikováno v:
Journal of managed carespecialty pharmacy.
Copanlisib was recently granted accelerated approval by the FDA for the treatment of adult patients with relapsed follicular lymphoma (FL) after 2 previous systemic therapies. It is important to assess the effect that this and other changes in the tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8605354c1383c8e262d11af3f812dd1f
https://pubmed.ncbi.nlm.nih.gov/30608008
https://pubmed.ncbi.nlm.nih.gov/30608008
Autor:
Robert C.G. Martin, Joanne Imperial, Jean Francois H. Geschwind, Pierre M. Gholam, Parvez S. Mantry, Allen Lee Cohn, Svetlana Babajanyan, Bilal Piperdi, Alec Goldenberg, Pamela K. Foreman, Ellen Zigmont
Publikováno v:
Liver Cancer. 5:37-46
Background: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Treatment with Sorafenib (GIDEON) is a worldwide, prospective, non-interventional study to evaluate the safety of sorafenib in a variety of patient subsets.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f78e85319937296f587c5d31cf36e281
https://doi.org/10.1159/000367757
https://doi.org/10.1159/000367757
Autor:
Danny Y. Song, Robert Given, Svetlana Babajanyan, Yoriko De Sanctis, Mark Perlmutter, Constantine Mantz, John Sylvester, Lauren C. Harshman, A. Oliver Sartor, Tim Richardson, Robert K. Brookland, Celestia S. Higano, Jan Kalinovsky
Publikováno v:
Journal of Clinical Oncology. 36:233-233
233 Background: Ra-223, a targeted alpha therapy, extended survival and had a favorable safety profile at 3 years’ follow up in pts with mCRPC in the pivotal phase 3 ALSYMPCA trial. The maturing global, prospective, single-arm, observational REASSU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3be0816de995eb769d11a6aa7c2caae5
https://doi.org/10.1200/jco.2018.36.6_suppl.233
https://doi.org/10.1200/jco.2018.36.6_suppl.233